ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of EUR 27.45 billion. The enterprise value is 26.96 billion.

Market Cap	27.45B
Enterprise Value	26.96B

Important Dates

The next confirmed earnings date is Thursday, April 30, 2026.

Earnings Date	Apr 30, 2026
Ex-Dividend Date	Feb 12, 2026

Share Statistics

Current Share Class	145.04M
Shares Outstanding	n/a
Shares Change (YoY)	-0.43%
Shares Change (QoQ)	-0.36%
Owned by Insiders (%)	0.52%
Owned by Institutions (%)	76.01%
Float	144.15M

Valuation Ratios

The trailing PE ratio is 21.69 and the forward PE ratio is 18.98.

PE Ratio	21.69
Forward PE	18.98
PS Ratio	5.97
PB Ratio	5.10
P/TBV Ratio	11.32
P/FCF Ratio	17.99
P/OCF Ratio	16.83
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.30, with an EV/FCF ratio of 17.67.

EV / Earnings	21.31
EV / Sales	5.86
EV / EBITDA	15.30
EV / EBIT	17.10
EV / FCF	17.67

Financial Position

The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.13.

Current Ratio	3.06
Quick Ratio	1.97
Debt / Equity	0.13
Debt / EBITDA	0.41
Debt / FCF	0.47
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 25.68% and return on invested capital (ROIC) is 26.60%.

Return on Equity (ROE)	25.68%
Return on Assets (ROA)	14.75%
Return on Invested Capital (ROIC)	26.60%
Return on Capital Employed (ROCE)	25.44%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	433,734
Profits Per Employee	119,389
Employee Count	10,600
Asset Turnover	0.69
Inventory Turnover	2.15

Taxes

In the past 12 months, ResMed has paid 283.46 million in taxes.

Income Tax	283.46M
Effective Tax Rate	18.30%

Stock Price Statistics

The stock price has decreased by -8.15% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-8.15%
50-Day Moving Average	202.64
200-Day Moving Average	219.83
Relative Strength Index (RSI)	36.82
Average Volume (20 Days)	1

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.27

Income Statement

In the last 12 months, ResMed had revenue of EUR 4.60 billion and earned 1.27 billion in profits. Earnings per share was 8.61.

Revenue	4.60B
Gross Profit	2.83B
Operating Income	1.57B
Pretax Income	1.55B
Net Income	1.27B
EBITDA	1.72B
EBIT	1.57B
Earnings Per Share (EPS)	8.61

Balance Sheet

The company has 1.21 billion in cash and 722.00 million in debt, giving a net cash position of 484.91 million.

Cash & Cash Equivalents	1.21B
Total Debt	722.00M
Net Cash	484.91M
Net Cash Per Share	n/a
Equity (Book Value)	5.38B
Book Value Per Share	36.96
Working Capital	2.19B

Cash Flow

In the last 12 months, operating cash flow was 1.63 billion and capital expenditures -104.66 million, giving a free cash flow of 1.53 billion.

Operating Cash Flow	1.63B
Capital Expenditures	-104.66M
Depreciation & Amortization	153.51M
Net Borrowing	-8.55M
Free Cash Flow	1.53B
FCF Per Share	n/a

Margins

Gross margin is 61.47%, with operating and profit margins of 34.19% and 27.53%.

Gross Margin	61.47%
Operating Margin	34.19%
Pretax Margin	33.69%
Profit Margin	27.53%
EBITDA Margin	37.51%
EBIT Margin	34.19%
FCF Margin	33.19%

Dividends & Yields

This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 1.06%.

Dividend Per Share	2.00
Dividend Yield	1.06%
Dividend Growth (YoY)	3.66%
Years of Dividend Growth	4
Payout Ratio	23.25%
Buyback Yield	0.43%
Shareholder Yield	1.50%
Earnings Yield	4.61%
FCF Yield	5.56%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ResMed has an Altman Z-Score of 12.89 and a Piotroski F-Score of 6.

Altman Z-Score	12.89
Piotroski F-Score	6